GNS Healthcare, a Cambridge, Mass.-based startup using artificial intelligence to develop precision medicine solutions, announced on July 9 the close of a $23 million funding round led by Cigna Ventures.
Other participants in the Series D round include Celgene and the venture arm of Amgen, as well as Echo Health Ventures, Alexandria Venture Investments and Gary Loveman, PhD, former president of consumer health and services at Aetna.
GNS Healthcare, which has raised nearly $80 million since it spun out of Gene Network Sciences in 2010, uses causal machine learning, trained on clinical trial data and real-world data, to model patient response to potential treatments; the company also shares that information with partners in biotech for drug discovery. From there, the GNS platform can help health plans identify which patients will best respond to which treatment, and when.
Date: July 15, 2019
Source: Becker’s Hospital Review